January 30, 2009 -- Sinobiopharma, Inc. reported much improved results from its wholly owned (and only) operating subsidiary, Dong Ying China, for the six-month period ended November 30, 2008. The most positive item in the report was the company’s revenues, which jumped 220% to $1.9 million. Almost all of the company’s sales came from Cisatracurium Besylate, a skeletal muscle relaxant, which contributed $1.8 million to Sinobiopharma’s coffers. More details... Stock Symbol: (OTCBB: SNBP)
